Diabetic Macular Edema (DME) Treatment Market Size, Share and Growth Outlook, 2026

Diabetic Macular Edema (DME) Treatment Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Diabetic Macular Edema (DME) Treatment Market size is forecast to increase from $5.79 Billion in 2026 to $7.57 Billion in 2034 at a CAGR of 3.4% between 2026 and 2034.

The Diabetic Macular Edema (DME) Treatment market report provides detailed analysis and outlook of Diabetic Macular Edema (DME) Treatment segments including By Drug Type (Anti-VEGF Therapy, Corticosteroid Therapies, Non-Steroidal Anti-Inflammatory Drugs ), By Treatment Modality (Intravitreal Injections, Intravitreal Implants, Laser Photocoagulation, Combination Therapy), By End User (Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Diabetic Macular Edema (DME) Treatment Industry Overview

The diabetic macular edema (DME) treatment industry is undergoing significant transformation as healthcare providers seek therapies that improve visual outcomes while reducing treatment burden for patients with diabetes-related retinal disease. Diabetic macular edema remains one of the leading causes of vision impairment among diabetic populations, driven by fluid accumulation and vascular leakage within the macula. Advances in sustained drug delivery systems, extended-duration anti-vascular endothelial growth factor (anti-VEGF) therapies, and novel inflammatory pathway-targeting treatments are reshaping the treatment landscape. The industry is increasingly focused on improving patient adherence, reducing injection frequency, maintaining long-term visual acuity, and addressing patients who exhibit inadequate responses to conventional biologic therapies. As a result, innovation across the diabetic macular edema treatment market is centered on long-acting retinal therapeutics, personalized treatment regimens, and alternative disease-modifying mechanisms.

Sustained Drug Delivery Technologies Reducing Treatment Burden

A major trend driving the diabetic macular edema treatment industry is the adoption of long-acting ocular drug delivery systems that minimize the need for frequent intravitreal injections. Roche achieved a significant milestone with the U.S. Food and Drug Administration approval of Susvimo® (ranibizumab injection, 100 mg/mL) for diabetic macular edema. Supported by positive Phase III Pagoda study results, the therapy utilizes a surgically implanted refillable port delivery platform that continuously releases medication directly into the eye.
Unlike traditional anti-VEGF regimens that often require monthly injections, the Susvimo® system provides sustained intraocular drug administration and requires only two routine office-based refill procedures annually to maintain therapeutic effectiveness and visual acuity. This advancement represents a major evolution in diabetic macular edema management by reducing treatment frequency while ensuring continuous disease control. The increasing adoption of sustained-release ophthalmic devices, implantable ocular drug delivery systems, anti-VEGF therapies, and long-acting retinal treatment technologies is transforming the diabetic macular edema treatment market by improving convenience and long-term patient adherence.

Extended-Duration Anti-VEGF Therapies Enhancing Disease Management

Another key trend shaping the diabetic macular edema treatment industry is the development of therapies that allow for longer intervals between maintenance treatments. Regeneron Pharmaceuticals secured FDA approval for an expanded label update for Eylea HD (aflibercept) 8 mg, enabling retina specialists to extend dosing intervals up to 20 weeks in eligible patients with diabetic macular edema and neovascular age-related macular degeneration.
The approval highlights a growing industry focus on reducing procedural burden without compromising treatment efficacy. By maintaining control over retinal fluid accumulation and vascular leakage while significantly reducing injection frequency, extended-duration anti-VEGF therapies support improved patient compliance and more efficient disease management. As clinicians increasingly seek individualized treatment strategies, high-dose anti-VEGF therapies, extended-interval retinal injections, and long-acting ophthalmology treatments are becoming important growth drivers within the diabetic macular edema treatment market.

Novel Non-VEGF Therapeutic Mechanisms Expanding Treatment Options

The diabetic macular edema treatment industry is also witnessing increased investment in therapies that target biological pathways beyond vascular endothelial growth factor inhibition. Clinical-stage biotechnology company Therini Bio initiated a Phase 1b clinical trial evaluating THN391, an intravitreal antibody specifically designed to address fibrin-driven retinal inflammation. Unlike conventional DME treatments that primarily focus on suppressing VEGF activity, THN391 targets inflammatory processes associated with persistent retinal swelling and vascular dysfunction.
This innovative approach is particularly relevant for patients who demonstrate suboptimal responses to standard anti-VEGF biologic therapies. By addressing inflammation-driven disease mechanisms, THN391 has the potential to expand treatment options for difficult-to-treat diabetic macular edema cases. The emergence of non-VEGF retinal therapies, inflammation-targeted biologics, intravitreal antibody treatments, and next-generation ophthalmology drugs reflects a broader shift toward diversified therapeutic strategies within the diabetic macular edema treatment industry. As sustained drug delivery systems, extended-duration anti-VEGF therapies, and novel retinal inflammation treatments continue to advance, they are redefining the future of diabetic macular edema management and retinal disease care.

Diabetic Macular Edema (DME) Treatment Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Diabetic Macular Edema (DME) Treatment market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Regeneron Pharmaceuticals, Inc., Bayer AG, F. Hoffmann-La Roche Ltd. (Genentech), Novartis AG, AbbVie Inc. (Allergan), Bausch Health Companies Inc., Sandoz Group AG, Oculis Holding AG, Alimera Sciences, Inc., Kodiak Sciences Inc.. The Diabetic Macular Edema (DME) Treatment market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Diabetic Macular Edema (DME) Treatment industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Diabetic Macular Edema (DME) Treatment Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Diabetic Macular Edema (DME) Treatment companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Diabetic Macular Edema (DME) Treatment markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Diabetic Macular Edema (DME) Treatment Market Competitive Benchmarking and Company Analysis

Leading companies in Diabetic Macular Edema (DME) Treatment industry include- Regeneron Pharmaceuticals, Inc., Bayer AG, F. Hoffmann-La Roche Ltd. (Genentech), Novartis AG, AbbVie Inc. (Allergan), Bausch Health Companies Inc., Sandoz Group AG, Oculis Holding AG, Alimera Sciences, Inc., Kodiak Sciences Inc.. The Diabetic Macular Edema (DME) Treatment market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Diabetic Macular Edema (DME) Treatment Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Diabetic Macular Edema (DME) Treatment market remains one of the strongest-performing segments in the country.
The US Diabetic Macular Edema (DME) Treatment Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Diabetic Macular Edema (DME) Treatment market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Diabetic Macular Edema (DME) Treatment industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Diabetic Macular Edema (DME) Treatment markets

Canada's strong Diabetic Macular Edema (DME) Treatment sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Diabetic Macular Edema (DME) Treatment market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Diabetic Macular Edema (DME) Treatment Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Diabetic Macular Edema (DME) Treatment market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Diabetic Macular Edema (DME) Treatment population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Diabetic Macular Edema (DME) Treatment industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Diabetic Macular Edema (DME) Treatment market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Diabetic Macular Edema (DME) Treatment sales through 2034

France Diabetic Macular Edema (DME) Treatment companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Diabetic Macular Edema (DME) Treatment Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Diabetic Macular Edema (DME) Treatment distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Diabetic Macular Edema (DME) Treatment Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Diabetic Macular Edema (DME) Treatment market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Diabetic Macular Edema (DME) Treatment industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Diabetic Macular Edema (DME) Treatment industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Diabetic Macular Edema (DME) Treatment Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Diabetic Macular Edema (DME) Treatment market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Diabetic Macular Edema (DME) Treatment market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Diabetic Macular Edema (DME) Treatment Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Diabetic Macular Edema (DME) Treatment Market Segmentation

By Drug Type
Anti-VEGF Therapy
Corticosteroid Therapies
Non-Steroidal Anti-Inflammatory Drugs
By Treatment Modality
Intravitreal Injections
Intravitreal Implants
Laser Photocoagulation
Combination Therapy
By End User
Hospitals
Ophthalmology Clinics
Ambulatory Surgical Centers

Top Companies in Diabetic Macular Edema (DME) Treatment Industry

Regeneron Pharmaceuticals, Inc.
Bayer AG
F. Hoffmann-La Roche Ltd. (Genentech)
Novartis AG
AbbVie Inc. (Allergan)
Bausch Health Companies Inc.
Sandoz Group AG
Oculis Holding AG
Alimera Sciences, Inc.
Kodiak Sciences Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025